Trials / Recruiting
RecruitingNCT06589713
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Phase 1, Open Label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Enpatoran in Male and Female Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics of enpatoran.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enpatoran | Participants will receive a single oral dose of enpataron tablets once daily. |
Timeline
- Start date
- 2024-09-24
- Primary completion
- 2026-04-15
- Completion
- 2026-07-28
- First posted
- 2024-09-19
- Last updated
- 2026-02-05
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06589713. Inclusion in this directory is not an endorsement.